Celiac disease future or investigational therapies
Celiac disease Microchapters |
Diagnosis |
---|
Treatment |
Medical Therapy |
Case Studies |
Celiac disease future or investigational therapies On the Web |
American Roentgen Ray Society Images of Celiac disease future or investigational therapies |
Celiac disease future or investigational therapies in the news |
Risk calculators and risk factors for Celiac disease future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Experimental treatments
Various other approaches are being studied that would reduce the need of dieting. All are still under development, and are not expected to be available to the general public for a while:
- Genetically engineered wheat species, or wheat species that have been selectively bred to be minimally immunogenic. This, however, could interfere with the effects that gliadin has on the quality of dough.
- A combination of enzymes (prolyl endopeptidase and a barley glutamine-specific cysteine endopeptidase (EP-B2)) that degrade the putative 33-mer peptide in the duodenum. This combination would enable coeliac disease patients to consume gluten-containing products.[1]
- Inhibition of zonulin, an endogenous signaling protein linked to increased permeability of the bowel wall and hence increased presentation of gliadin to the immune system.[2]
- Other treatments aimed at other well-understood steps in the pathogenesis of coeliac disease, such as the action of HLA-DQ2 or tissue transglutaminase and the MICA/NKG2D interaction that may be involved in the killing of enterocytes (bowel lining cells).
References
- ↑ Siegel M, Bethune M, Gass J, Ehren J, Xia J, Johannsen A, Stuge T, Gray G, Lee P, Khosla C (2006). "Rational design of combination enzyme therapy for celiac sprue". Chem Biol. 13 (6): 649–58. PMID 16793522.
- ↑ Fasano A, Not T, Wang W, Uzzau S, Berti I, Tommasini A, Goldblum S (2000). "Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease". Lancet. 355 (9214): 1518–9. PMID 10801176.